The balance of estrogen metabolites in breast cancer and the ways of its correction

Background. A clear relationship is now found between the activity of estrogen metabolites and the development of tumors in estrogen-dependent tissues. Many international and Russian studies could identify a number of compounds involved in the regulation of estrogen metabolites. Indole-3-carbinol is one of these compounds that correct a ratio of 2-hydroxyestrone (2-OHE1) to 16-OHE1. It is a phytonutrient that is contained in Cruciferous vegetables and has antitumor activity. Our investigations used highly purified indole-3-carbinol (Indinol). The ability to identify the role of metabolic syndrome, by applying the current methodological approaches, allowed us to study the effect of highly purified indole-3-carbinol on the level of expression of estrogen metabolites and to attempt to expand views on procedures to prevent and treat breast tumors.
Materials and methods. A total of 136 women were comprehensively examined; of them 44 patients formed a group of those with morphologically verified hormone-independent breast cancer (BC) and 42 patients were a group of those with hormone-dependent BC. A control group included 50 women without signs of breast disease. In all the patients, body mass index was calculated; the ratio of urinary estrogen metabolites (2-ОНЕ1/16α-ОНЕ1) was quantified; and biopsy specimens and operative material were histologically and immunohistologically studied.
Results. The BC patients were noted to have the high expression of 16α-OHE1 and the low values of 2-OHE1 (ratio, 0.42) as compared to the control group (2.09), which was an important component of metabolic syndrome. The BC patients had the high level of concomitant endocrine metabolic disturbances with the high body mass index, which reflected the clinical manifestation of metabolic syndrome. Indinol used to treat both hormone-dependent and hormone-independent BC showed an antimetabolic effect that was most pronounced 6 months later. Conclusion. Thus, early correction of metabolic disturbances with antimetabolites is one of the important, pathogenetically sound areas in the prevention of BC. 

1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М., 2014. 226 с. [Statistics of malignant tumors in Russia and CIS countries in 2012. Ed. by М.I. Davydov, Е.М. Аxel. Мoscow, 2014. 226 p. (In Russ.)].

2. Рожкова Н.И., Меских Е.В. Оценка эффективности препарата индинол при лечении различных форм мастопатии. Материалы V Всероссийской научно-практической конференции «Организационные медицинские и технические аспекты клинической маммологии. М., 2007. C. 149. [Rozhkova N.I., Меskikh Е.V. Evaluation of the efficacy of indinol substance at the treatment of different forms of mastopathy. Маterials of the V All-Russian scientific and practical conference “Оrganizational medical and technical aspects of the clinical mammology”. Мoscow, 2007. P. 149. (In Russ.)].

3. Crowe J.P. Jr, Gordon N.H., Hubay C.A. et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1999;173:273–8.

4. White R., Parker M.G., Molekular mechanism of steroid hormone action. End Related Cancer 1998;5:1–14.

5. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207–13.

6. Frasor J., Danes J.M., Komm B. еt al. Profiling of estrogen upand down-regulated gene expression in human breast cancers cells:insights into gene networks and pahtways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562–74.

7. Swaneck G.E., Fishman J. Covalent binding of the endogenous estrogen 16 alрfahydroxyesterone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1998;85:7831–35.

8. Киселев В.И., Ляшенко А.А. Молекулярные механизмы регуляции гиперпластических процессов. М., 2005. [Kiselev V.I., Lyashenko А.А. Molecular mechanisms of the regulation of hyperplastic processes. Мoscow, 2005. (In Russ.)].

9. Сlemons M., Goss P. Estrogen and risk of breast cancer. N Engl J Med 2001;344(4): 276–85.

10. Segars J.H., Driggers P.H. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. TRENDS Endocrinol Metab 2002;13(8): 349–54.

11. Key T.J., Schatzkin A., Willett W.C. et al. Diet, nutrition and the prevention of cancer. Pablik Health Nutr 2004;7(1A):187–200.

12. Rahman K.M., Aranha O., Sarkar F.H. Indol-3 carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 2003;45(1): 101–12.

13. Киселев А.А., Киселев В.И., Северин Е.С. Индол-3-карбинол (Индинол): терапевтические и профилактические эффекты на клетки опухолей молочной железы. Молекулярная медицина 2005;2:20–5. [Kiselev А.А., Kiselev V.I., Severin Е.S. Indol-3-carbinol (Indinol): therapeutic and prophylactic effects on cells of breast tumors. Molekulyarnaya meditsina = Моlecular medicine 2005;2:20–5. (In Russ.)].

14. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивных органов (этиология и патогенез). М., 2007. [Аshrafyan L.А., Kiselev V.I. Tumors of reproductive organs (etiology and pathogenesis). Мoscow, 2007. (In Russ.)].

15. Моисеенко В.М. Естественная история роста рака молочной железы. Практическая онкология. Избранные лекции. Под ред. С.А. Тюляндина, В.М. Моисеенко. М., 2004. C. 22–3. [Моiseenko V.М. Natural history of the breast cancer growth. Selected lectures. Ed. by S.А. Тulyandin, V.М. Моiseenko. Мoscow, 2004. Pp. 22–3. (In Russ.)].

16. Eibl G., Bruemmer D., Okada Y. et al. Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. Maturitas 2004;49(1):16–24.

17. Мельниченко Г.А. Ожирение в практике эндокринолога. Русский медицинский жур-

18. нал. 2001;9(2):82–7. [Меlnichenko G.А. Оbesity in endocrinologist’s practice. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2001;9(2):82–7. (In Russ.)].

19. Walker R.A., Harris A.L., Balslev E. Immunohistochemistry and сancer. Diagnosis. Therapy and prognosis. Corporate Headguartes Denmark, 2004. P. 23.

20. Берштейн Л.М., Зимарина Т.С., Цырлина Е.В. и др. Генетический полиморфизм ферментов стероидогенеза и содержание рецепторов в опухолях репродуктивной системы. Вопросы онкологии 2004;50(2):169–73. [Berstein L.М., Zimarina Т.S., Tsyrlina Е.V. et al. Genetic polymorphism of steroidogenesis enzymes and receptors’ content in reproductive system tumors. Voprosy onkologii = Cancer Issues 2004;50(2):169–73. (In Russ.)].

21. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Русский медицинский журнал 2001;9(2):56–60. [Butrovа S.А. Меtabolic syndrome: pathogenesis, clinic, diagnosis, treatment approaches. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2001;9(2):56–60. (In Russ.)].

22. Bredlow H.L. Nutrient modulation of female hormone metabolism, modifying brest cancer risk. In: Fanctional medicine approaches to endocrine disturbances of aging. Vancouver, British Columbia: Institute of Functional Medicine Proceedings, 2001.

23. Guilemette C., Belanger A., Lepine J. Metabolic inactivaition of estrogens in brest tissue by UDP-glucuronosyltransferase enzymes: an overview. Brest Cancer Res 2004;6(6):246–54.

24. Rogan E.G., Badawi A.F., Devanesan P.D. et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis (Engl) 2003;24(4):697–702.

25. Tang S., Han H., Bajic V.B. ERGDB estrogen responsive genes database. Nucleic Acids Res 2004;32(Database issue):D533–6. 25. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000;21:427–33.